EP2021482A1 - Traitement d'une infection par un virus à arn à une arn polymérase arn dépendante - Google Patents
Traitement d'une infection par un virus à arn à une arn polymérase arn dépendanteInfo
- Publication number
- EP2021482A1 EP2021482A1 EP07765973A EP07765973A EP2021482A1 EP 2021482 A1 EP2021482 A1 EP 2021482A1 EP 07765973 A EP07765973 A EP 07765973A EP 07765973 A EP07765973 A EP 07765973A EP 2021482 A1 EP2021482 A1 EP 2021482A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sequence
- virus
- nucleic acid
- rna
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 37
- 108060004795 Methyltransferase Proteins 0.000 title claims abstract description 17
- 208000015181 infectious disease Diseases 0.000 title claims description 17
- 238000011282 treatment Methods 0.000 title description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 206
- 241000711549 Hepacivirus C Species 0.000 claims abstract description 147
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 86
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 83
- 230000010076 replication Effects 0.000 claims abstract description 70
- 230000000295 complement effect Effects 0.000 claims abstract description 59
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 57
- 108020003589 5' Untranslated Regions Proteins 0.000 claims abstract description 44
- 239000013598 vector Substances 0.000 claims abstract description 41
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 35
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 29
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 29
- 108091092724 Noncoding DNA Proteins 0.000 claims abstract description 18
- 230000003362 replicative effect Effects 0.000 claims abstract description 14
- 241001493065 dsRNA viruses Species 0.000 claims abstract description 13
- 230000002452 interceptive effect Effects 0.000 claims abstract description 9
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 44
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 22
- 230000003612 virological effect Effects 0.000 claims description 22
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 claims description 14
- 108010039491 Ricin Proteins 0.000 claims description 13
- 208000005176 Hepatitis C Diseases 0.000 claims description 10
- 230000030833 cell death Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 231100000654 protein toxin Toxicity 0.000 claims description 9
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 8
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 108700012359 toxins Proteins 0.000 claims description 6
- 108091054729 IRF family Proteins 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 108010080611 Cytosine Deaminase Proteins 0.000 claims description 4
- 102000000311 Cytosine Deaminase Human genes 0.000 claims description 4
- 102000041192 Type 2 family Human genes 0.000 claims description 4
- 108091061186 Type 2 family Proteins 0.000 claims description 4
- 108010066676 Abrin Proteins 0.000 claims description 3
- 241000710781 Flaviviridae Species 0.000 claims description 3
- 102000016854 Interferon Regulatory Factors Human genes 0.000 claims description 3
- 108010079723 Shiga Toxin Proteins 0.000 claims description 3
- 239000002095 exotoxin Substances 0.000 claims description 3
- 231100000776 exotoxin Toxicity 0.000 claims description 3
- 108010010621 modeccin Proteins 0.000 claims description 3
- 239000002636 mycotoxin Substances 0.000 claims description 3
- 230000029812 viral genome replication Effects 0.000 claims description 3
- 108010043904 volkensin Proteins 0.000 claims description 3
- KQNNSYZQMSOOQH-GLDAUDTLSA-N volkensin Chemical compound C=1([C@@H]2C[C@@H]3O[C@@H](O)C[C@@H]4[C@]5(C)[C@H]6[C@H]([C@H]([C@@]4(C)C3=C2C)O)OC[C@]6(C)[C@H](OC(C)=O)C[C@@H]5OC(=O)C(/C)=C/C)C=COC=1 KQNNSYZQMSOOQH-GLDAUDTLSA-N 0.000 claims description 3
- 241000712892 Arenaviridae Species 0.000 claims description 2
- 241001533362 Astroviridae Species 0.000 claims description 2
- 241000702628 Birnaviridae Species 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000714198 Caliciviridae Species 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 241000702221 Cystoviridae Species 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 241000711950 Filoviridae Species 0.000 claims description 2
- 241000712464 Orthomyxoviridae Species 0.000 claims description 2
- 241000711504 Paramyxoviridae Species 0.000 claims description 2
- 241000150350 Peribunyaviridae Species 0.000 claims description 2
- 241000709664 Picornaviridae Species 0.000 claims description 2
- 241001533393 Potyviridae Species 0.000 claims description 2
- 241000702247 Reoviridae Species 0.000 claims description 2
- 241000711931 Rhabdoviridae Species 0.000 claims description 2
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 2
- 108020004440 Thymidine kinase Proteins 0.000 claims description 2
- 241000710924 Togaviridae Species 0.000 claims description 2
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 241000725619 Dengue virus Species 0.000 claims 1
- 238000013518 transcription Methods 0.000 abstract description 16
- 230000035897 transcription Effects 0.000 abstract description 16
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 85
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 56
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 56
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 230000000875 corresponding effect Effects 0.000 description 17
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 17
- 230000014616 translation Effects 0.000 description 14
- 102000006992 Interferon-alpha Human genes 0.000 description 13
- 108010047761 Interferon-alpha Proteins 0.000 description 13
- 238000013519 translation Methods 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 125000002652 ribonucleotide group Chemical group 0.000 description 10
- 102100024365 Arf-GAP domain and FG repeat-containing protein 1 Human genes 0.000 description 9
- 108010076039 Polyproteins Proteins 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 6
- 108091028664 Ribonucleotide Proteins 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 239000002336 ribonucleotide Substances 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108090000565 Capsid Proteins Proteins 0.000 description 4
- 102100023321 Ceruloplasmin Human genes 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 238000002473 ribonucleic acid immunoprecipitation Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 2
- -1 8-bromσ guanosine Chemical class 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 102000043138 IRF family Human genes 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 108010002685 hygromycin-B kinase Proteins 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 108700024542 myc Genes Proteins 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 244000144619 Abrus precatorius Species 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241001639638 Adenia volkensii Species 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 241000607516 Aeromonas caviae Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101800001603 Capsid protein C Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 101800001847 Core protein precursor Proteins 0.000 description 1
- 241001275954 Cortinarius caperatus Species 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000214054 Equine rhinitis A virus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241001529916 Hepatitis GB virus B Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000682990 Pegivirus A Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 208000009341 RNA Virus Infections Diseases 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 101100285899 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SSE2 gene Proteins 0.000 description 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 1
- 108010017898 Shiga Toxins Proteins 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 108700022715 Viral Proteases Proteins 0.000 description 1
- 241000221012 Viscum Species 0.000 description 1
- 241000221013 Viscum album Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000005642 phosphothioate group Chemical group 0.000 description 1
- 229930000184 phytotoxin Natural products 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- HDZZVAMISRMYHH-KCGFPETGSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HDZZVAMISRMYHH-KCGFPETGSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 108010071260 virus protein 2A Proteins 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24241—Use of virus, viral particle or viral elements as a vector
- C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to a nucleic acid molecule, a pharmaceutical composition comprising such a nucleic acid molecule and the use of such a nucleic acid molecule for the preparation of a medicament for treating or preventing an infection. by an RNA virus replicating with a RNA-dependent RNA polymerase, and in particular infection with the hepatitis C virus.
- Hepatitis C virus is now a major public health problem, given the high prevalence of hepatitis C infection and the significant risk of later progression to chronic hepatitis. order of 80%. Indeed, the hepatitis C virus (HCV) infects about 3% of the population and is responsible for approximately 170 million cases of chronic infections. Patients with such a chronic infection are then likely to develop cirrhosis, with a risk estimated at 20-30% twenty years after the primary infection, which can evolve into hepatocarcinoma. Since primary infection is usually asymptomatic, the infection is diagnosed when the complications of chronic infection occur.
- HCV is a positive RNA virus belonging to the Flaviviridae family, discovered by CHIRON in 1989 (KUO et al., Science, 244 (4902), p: 362-4, 1989). Fine molecular analyzes have shown that there are nearly 6 different genotypes of HCV, which genotypes are subdivided into multiple subtypes. Most HCV infections are associated with genotype 1.
- HCV genomic RNA contains a single open reading frame framed by non-coding sequences in 5 '(5'UTR) and in 3'(3'UTR). If the 5'UTR sequence shows significant conservation regardless of the genotype studied, the 3'UTR sequence shows significant variability in its first 30 nucleotides depending on the genotype studied.
- the open reading phase codes according to the genotype considered for a polyprotein of 3008 to 3037 amino acids, which is cleaved in a co- and post-translational way by cellular and viral proteases to generate at least 10 mature viral proteins involved in the replication and morphogenesis of new virions. More specifically, the structural proteins are located in the amino-terminal third of said polyprotein and the nonstructural proteins, some of which form the replication complex, in the carboxy-terminal portion of the polyprotein.
- the 5'UTR region contains an internal ribosome entry site that allows the viral genome (strand (+)), following internalization of the virion, to be translated cap-independently.
- the replication complex assembles, and then the RNA-dependent RNA polymerase (NS5B) begins replicating the RNA.
- the HCV replication complex is therefore present in all the infected cells.
- viruses with an RNA genome replicate through a RNA-dependent RNA polymerase (RdRp) that synthesizes, from genomic RNA, a RNA of opposite polarity serving as replication intermediate.
- This replication intermediate RNA is in turn copied by the RNA dependent RNA polymerase to regenerate the genomic RNA.
- This RdRp is coded by the virus and develops its activity within a replication complex, some of whose proteins are also encoded by the virus. Sequences carried by the viral genome are essential for the fixation of the replication complex which precedes the synthesis of the opposite RNA strand by the RdRp.
- This replication complex binds to the untranslated region 3 'of the viral genome to synthesize the negative strand from the positive genomic strand. Subsequently this replication complex binds to the untranslated region located 5 'of the negative strand to synthesize the positive genomic strand.
- the replication complex of the virus having an RNA genome replicating with a RNA-dependent RNA polymerase is therefore present in all the infected cells.
- the two 5'UTR and 3'UTR sequences are indispensable.
- the 3'UTR sequence is necessary for the synthesis of the (-) strand from the (+) strand.
- the 5'UTR sequence is necessary for the synthesis of (+) strands of the new virions from the (-) strand.
- the 5'UTR region has a length of the order of 340 nucleotides.
- This 5'UTR region comprises four domains presenting a stem-loop structure (5'UTR-dI domains at 5'UTR-dIV), the last 5 'UTR-d1V domain being overlapping with the first nucleotides of the corresponding coding phase to the capsid protein of the polyprotein.
- This 5'UTR region is strongly conserved between the different strains of HCV, both at the nucleotide sequence and at the structural level. In addition to its role in genome replication, the 5'UTR region is also involved in initiation of the translation of the polyprotein.
- the minimal domain of the 5'UTR region for replication to occur includes the 5'UTR-dI and 5'UTR-dII domains (FRIEBE et al., J. Virol., Vol.75 (24), p: 12047-57, 2001), the 5'UTR-dIII domain playing a modulating role on it (REUSKEN et al., J. Gen. Virol., Vol.84, p: 1761-69, 2003).
- the minimal domain for HCV translation corresponds to an internal ribosome entry site (IRES) to which the ribosome is directly attached (HONDA et al., Virology, vol.222 (1), p: 31-42, 1996). ) which allows an initiation of cap-independent translation.
- IRES internal ribosome entry site
- the 5'UTR-dII domains at 5'UTR-dIV are necessary for the initiation of the translation.
- the location of the 3 'end of the IRES is controversial.
- HCV RNA-dependent RNA polymerase
- NS5B RNA-dependent RNA polymerase
- NS3 viral protease NS3
- a suicide vector in the form of a chimeric genomic RNA of negative polarity which will be replicated to a chimeric genomic RNA of positive polarity only in the cells infected with HCV (cells expressing the complex HCV replication), which chimeric genomic RNA of positive polarity allows the translation of a toxic protein whose expression causes death of HCV-infected cells.
- the chimeric genomic RNA of negative polarity according to the invention thus makes it possible to overcome the problems mentioned above, in particular the variable efficiency as a function of the genotypes of the anti-HCV molecules of the treatments of the prior art and the great genetic variability to the basis of antiviral resistance.
- a first subject of the invention corresponds to a single-stranded RNA molecule, which comprises, starting from the 3 'end towards the 5' end:
- nucleic acid sequence complementary to a nucleic acid sequence corresponding to an internal ribosome entry site optionally, the nucleic acid sequence complementary to a nucleic acid sequence corresponding to an internal ribosome entry site (IRES);
- RNA of said virus optionally, a nucleic acid sequence complementary to the 3 'non-coding region (3'UTR) of the RNA of said virus.
- the single-stranded RNA molecule according to the invention is non-coding. Accordingly, said single-stranded RNA molecule, when present in non-virus infected cells of interest in which the replication complex is not expressed, does not allow to obtain the transcript of the suicide gene and its subsequent translation and thus to induce cell death.
- the single-stranded RNA molecule according to the invention when it is present in cells infected with the virus of interest which express the replication complex, is replicated in a complementary strand whose translation initiated at the level of the IRES sequence induces the synthesis of the suicide gene protein and, consequently, the cell death.
- the RNA molecule according to the invention comprises a nucleic acid sequence complementary to a nucleic acid sequence corresponding to an internal ribosome entry site (IRES).
- IRES internal ribosome entry site
- this sequence is not mandatory for viruses that do not require IRES for translation.
- Those skilled in the art can easily determine the viruses for which the RNA molecule according to the invention does not require a nucleic acid sequence complementary to a nucleic acid sequence corresponding to an internal ribosome entry site. (1RES).
- the RNA making it possible to obtain the complementary sequences (i) and (iv) is genomic RNA.
- RNA virus means a virus whose genomic RNA is directly coding.
- genomic RNA is meant the RNA strand which corresponds to the RNA encapsidated in the viral particle.
- a first subject of the invention corresponds to a single-stranded RNA molecule, corresponding to a chimeric genomic RNA of negative polarity (RNA (-)) of the hepatitis C virus (HCV), which molecule d RNA single strand is characterized in that it comprises starting from the end 3 'to the end 5':
- strand (+) of hepatitis C virus (HCV), which complementary nucleic acid sequence allows the replication of said single-stranded RNA molecule by the HCV replication complex;
- nucleic acid sequence complementary to the 3 'non-coding region (3'UTR) of the genomic RNA (strand (+)) of HCV optionally, a nucleic acid sequence complementary to the 3 'non-coding region (3'UTR) of the genomic RNA (strand (+)) of HCV.
- the RNA molecule according to the invention comprises a nucleic acid sequence complementary to the 5 'non-coding region (5'UTR) of the genomic RNA (strand (+)) of the virus of the hepatitis C (HCV), which complementary nucleic acid sequence allows the replication of said single-stranded RNA molecule by the HCV replication complex.
- 5'UTR 5 'non-coding region
- HCV hepatitis C
- the single-stranded RNA molecule according to the invention is non-coding.
- said single RNA molecule strand when present in non-HCV-infected cells in which the HCV replication complex is therefore not expressed, does not make it possible to obtain the transcript of the suicide gene and its consecutive translation and therefore of induce cell death.
- the single-stranded RNA molecule according to the invention when present in HCV-infected cells that express the replication complex, is replicated in a complementary strand (strand (+)) whose translation initiated. at the level of the sequence IRES induces the synthesis of the protein of the suicide gene and, consequently, the cell death.
- RNA molecules corresponding to a chimeric genomic RNA of negative polarity (strand (-)) of the hepatitis C virus makes it possible, unlike a chimeric genomic RNA of positive polarity (strand (+)), to avoid the replication step requiring the recognition of the sequence 3'UTR strand (+) to obtain its replication strand (-).
- RNA viruses that replicate using an RNA-dependent RNA polymerase
- RNA viruses that replicate with a RNA-dependent RNA polymerase are chosen from the group comprising:
- the single-stranded RNA molecule according to the invention may comprise modified or unmodified ribonucleotides, preferably said single-stranded RNA molecule comprises unmodified ribonucleotides.
- modified ribonucleotide is meant a natural ribonucleotide substituted with a synthetic analog of a nucleotide, which synthetic ribonucleotide analog is preferably located at the 3 'or 5' end of the nucleic acid molecule.
- Synthetic analogues of preferred nucleotides are selected from ribonucleotides having a sugar group or modified carbon group.
- the ribonucleotides having a modified sugar group have a 2'-OH group replaced by a group selected from a hydrogen atom, a halogen, a group OR, R, SH, SR, NH 2 , NHR, NR 2 or CN, wherein R is an alkyl, alkenyl or alkynyl group of 1 to 6 carbon and the halogen is fluorine, chlorine, bromine or iodine.
- the ribonucleotides having a modified carbon group have their phosphoester group attached to the adjacent ribonucleotide which is replaced by a modified group such as a phosphothioate group.
- a modified group such as a phosphothioate group.
- modified nuclei examples include, but are not limited to 5-substituted uridines or cytidines, such as 5- (2-amino) propyl uridine and 5-bromo uridine, 8-modified adenosines and guanosines, such as 8-brom ⁇ guanosine, denatured nucleotides, such as 7-deaza-adenosine, N- and O-alkylated nucleotides, such as N6-methyl adenosine. These different modifications can also be combined.
- 5-substituted uridines or cytidines such as 5- (2-amino) propyl uridine and 5-bromo uridine
- 8-modified adenosines and guanosines such as 8-brom ⁇ guanosine
- denatured nucleotides such as 7-deaza-adenosine
- N- and O-alkylated nucleotides such as
- nucleic acid sequence complementary to the 5 'non-coding region (5'UTR) of the genomic RNA (strand (+)) of HCV which complementary nucleic acid sequence allows the replication of said nucleic acid molecule.
- Single-stranded RNA by the HCV replication complex is understood to mean a nucleic acid sequence comprising at least the sequence complementary to a sequence comprising the stem-loop domains I and II (5'UTR-dI and 5 'UTR).
- the 5'UTR-dI domain ranges from nucleotides 5 to sequences having the accession number M62321, M67463 or AF009606 for the genotype 1a; 1 to 8 of the sequence having the accession number D90208 or 1 to 11 of the sequence having the accession number M58335 for the genotype Ib; 5 to 20 of the sequence having the accession number D14853 or AY051292 for the genotype Ic; 5 to 19 of the sequence having the accession number D00944 or AB047639 for the genotype 2a; 5 to 20 of the sequence having accession number D10988 or AB030907 for genotype 2b; 5 to 19 of the sequence having accession number D50409 for genotype 2c; 6 to 20 of the sequence having the accession number AB031663 for the genotype 2k; 5 to 18 of the sequence having accession number D17763 or D28917 for genotype 3a; 5 to 18 of the sequence having accession number D49374 for genotype 3b; 5
- the 5'UTR-dII domain ranges from nucleotides 44 to 118 for sequences having the accession number M62321, M67463 or AF009606 for the genotype 1a; 35 to 109 of the sequence having the accession number M58335 or 32 to 106 of the sequence having the accession number D90208 for the genotype Ib; 44 to 118 sequences having the accession number D14853 or AY051292 for the genotype Ic; 43 to 117, sequences having accession number D00944 or AB047639 for genotype 2a; 44 to 118 sequences having accession number AB030907 or D10988 for genotype 2b; 43 to 117 of the sequence having accession number D50409 for genotype 2c; 44 to 118 of the sequence having accession number AB031663 for genotype 2k; 42 to 116 of the sequence having accession number D17763 or D28917 for genotype 3a; 42 to 116 of the sequence having accession number D49374
- the 5'UTR-dIII domain ranges from nucleotides 125 to 323 with accession number M62321, M67463 or AF009606 for genotype 1a; 116 to 314 of the sequence having the accession number M58335 or 113 to 311 of the sequence having the accession number D90208 for the genotype Ib; 125 to 323 sequences having the accession number D14853 or AY051292 for the genotype Ic; 124 to 322 sequences having accession number D00944 or AB047639 for genotype 2a; 125 to 323 sequences having accession number AB030907 or D10988 for genotype 2b; 124 to 322 of the sequence having accession number D50409 for genotype 2c; 125 to 323 of the sequence having the accession number AB031663 for the genotype 2k; 123 to 321 sequences having accession number D17763 or D28917 for genotype 3a; 123 to 321 of the sequence having accession number having acces
- nucleic acid sequence complementary to the 5 'non-coding region (5'UTR) of the genomic RNA (strand (+)) of HCV which complementary nucleic acid sequence allows replication of said single-stranded RNA molecule by the HCV replication complex, the nucleic acid sequence complementary to the sequence from position 1 to 120 of the genomic RNA (strand (+)) of HCV, preferably comprising from position 1 to 150 and particularly preferably from position 1 to 341 of genomic RNA (strand (+)) of HCV.
- Position 1 corresponds to the first nucleotide of the genomic RNA (strand (+)) of a complete hepatitis C virus (HCV).
- 5'UTR region of the genomic RNA is meant the 5'UTR region of the genomic RNA of a genotype 1, 2, 3 hepatitis C virus (HCV). , 4, 5 or 6, or a sequence derived therefrom.
- derivative sequence is meant a sequence having an identity of at least 80% with the sequence of the 5'UTR region of the genomic RNA of a hepatitis C virus of genotype 1, 2, 3, 4, 5 or 6, preferably at least 85%, especially at least 90%, and particularly preferably at least 95% identity.
- the sequence of the 5'UTR region of the HCV genomic RNA corresponds to the sequence of the 5'UTR region of the genome RNA of a genotype 1 hepatitis C virus (HCV) virus. .
- HCV hepatitis C virus
- the sequence of the 5'UTR region of the HCV genomic RNA corresponds to the sequence from position 1 to 120 of the sequence SEQ ID No: 1, preferably from position 1 to 150 and particularly preferably from position 1 to 341 of the sequence SEQ ID No: 1 or a sequence derived therefrom.
- IRES internal ribosome entry site
- IRES sequence of eukaryotic origin mention may be made of the IRES sequence of the transcripts coding for the proteins chosen from the group comprising the FGF (Fibroblast Growth Factor) family, the connexin family, the p27 inhibitory protein of the cyclin-dependent kinase, BCL 2, HSP 101, HSP 70, c-myc proto-oncogenes, L-myc, n-myc or the Mnt transcriptional repressor.
- FGF Fibroblast Growth Factor
- IRES sequence of viral origin we can cite the IRES sequence of the polio virus, encephalomyocarditis virus (EMCV), GBV-A virus, GBV-B virus and GBV virus. -C, hepatitis C virus, bovine viral diarrhea virus (BVDV), equine rhinitis virus A and B (ERAV and ERBV), ZAM retroactive elements, Idefix and gypsy or HIV.
- EMCV encephalomyocarditis virus
- GBV-A virus GBV-A virus
- GBV-B virus and GBV virus GBV virus.
- -C hepatitis C virus
- bovine viral diarrhea virus (BVDV) bovine viral diarrhea virus
- EAV and ERBV equine rhinitis virus A and B
- ZAM retroactive elements Idefix and gypsy or HIV.
- the IRES sequence is of viral origin and, in a particularly preferred manner, said IRES sequence corresponds to the IRES sequence of HCV, which comprises the stem-loop domains II to IV (5'UTR-dII at 5 'UTR-dlV) of the 5'UTR region of genomic RNA (strand (+)) of HCV.
- sequence 1res of HCV ranges from nucleotides 44 to 354 sequences having the accession number M62321, M67463 or AF009606 for the genotype la; 35 to 345 of the sequence having the accession number M58335 or 32 to 342 of the sequence having the number accession D90208 for genotype Ib; 44 to 354 sequences having the accession number D14853 or AY051292 for the genotype Ic; 43 to 353 sequences having accession number D00944 or AB047639 for genotype 2a; 44 to 354 sequences having accession number AB030907 or D10988 for genotype 2b; 43 to 353 of the sequence having accession number D50409 for genotype 2c; 44 to 354 of the sequence having the accession number AB031663 for the genotype 2k; 42 to 352 sequences having accession number D17763 or D28917 for genotype 3a; 42 to 352 of the sequence having accession number D49374 for genotype 3b
- sequence 1res of HCV the sequence from position 30 to 355 of genomic RNA (strand (+)) of HCV, preferably from position 25 to 370 and particularly preferably from position 20 to 385 of the genomic RNA (strand (+)) of HCV.
- 1RES sequence of HCV is meant the IRES sequence of a genomic RNA (strand (+)) of a hepatitis virus (HCV) genotype 1, 2, 3, 4, 5 or 6, or a sequence derived therefrom, preferably the IRES sequence of the genomic RNA (strand (+)) of a genotype 1 hepatitis C virus (HCV).
- derivative sequence is meant a sequence having an identity of at least 80% with the sequence of the IRES sequence of the genomic RNA (strand (+)) of a hepatitis C virus (HCV) of genotype 1 , 2, 3, 4, 5 or 6, preferably at least 85%, especially at least 90%, and particularly preferably at least 95% identity.
- the 1RES sequence of HCV corresponds to the sequence from position 30 to 355 of the sequence SEQ ID No: 1, preferably from position 25 to 370 and particularly preferably from position 20 to 386 of the sequence SEQ ID No: 1 or a sequence derived therefrom.
- the single-stranded RNA molecule according to the invention comprises the sequence complementary to the sequence ranging from position 1 to
- genomic RNA (strand (+)) of HCV preferably from position 1 to 370 and particularly preferably from position 1 to 385 of the genomic RNA (strand (+)) of HCV.
- genomic RNA sequence (strand (+)) of HCV is meant the sequence of a hepatitis C virus (HCV) of genotype 1, 2, 3, 4, 5 or 6, or a derived sequence of this, preferably is the sequence of a hepatitis C virus (HCV) of genotype 1.
- derivative sequence is meant a sequence having an identity of at least 80% with the sequence of the genomic RNA (strand (+)) of a hepatitis C virus of genotype 1, 2, 3, 4, 5 or 6, preferably at least 85%, especially at least 90%, and particularly preferably at least 95% identity.
- the single-stranded RNA molecule according to the invention comprises the sequence complementary to the sequence ranging from position 1 to 355 of the sequence SEQ ID No: 1, preferably from position 1 to 370 and particularly preferably from position 1 to 386 of the sequence SEQ ID No: 1 or a sequence derived therefrom.
- proteins interfering with HCV replication include interferon ⁇ , interferon ⁇ and interferon ⁇ , preferably interferon ⁇ and particularly preferably interferon ⁇ 2 ⁇ or ⁇ 2b.
- genes coding for proteins interfering with the replication of a RNA virus that replicates using an RNA-dependent RNA polymerase in particular hepatitis C virus
- IRF interferon regulatory factor
- suicide gene is meant a gene that encodes a protein product that induces death of the cell in the presence or absence of drugs.
- the suicide gene codes for a bacterial or viral enzyme inducing the death of the cell in the presence of a specific "drug".
- said enzymes convert the inactive form of a drug (prodrug) present in the medium into its active and toxic form inducing cell death, for example by inhibition of nucleic acid synthesis.
- a drug prodrug
- said enzymes convert the inactive form of a drug (prodrug) present in the medium into its active and toxic form inducing cell death, for example by inhibition of nucleic acid synthesis.
- suicide genes include, but are not limited to, HSV thymidine kinase (HSVltk) or cytosine deaminase (CD) genes used respectively with Ganciclovir or 5-FU. respectively (see PCT International Application WO 2005/092374, pages 11 and 12).
- the suicide gene codes for a protein toxin inducing cell death.
- bacterial exotoxins As examples of usable proteins, mention may be made of bacterial exotoxins, fungal toxins, toxins of eukaryotic origin, of plant origin or of viral origin, or proteins derived therefrom.
- Distal protein means a protein having an identity of at least 80% with a bacterial exotoxin, a fungal toxin, a toxin of eukaryotic origin, of plant origin or viral origin, preferably at least 85%. %, especially at least 90%, and particularly preferably at least 95% identity.
- the protein toxin inducing the death of the cell belongs to the RIP family
- the proteins of the RIP family are related to the lectin family, but their toxicity is much greater than the latter.
- the proteins of the RIP family are divide into two types according to their molecular structure.
- Type I groups proteins that have a single polypeptide chain of about 30 kDa and lack lectin activity for cell-surface attachment, which gives them low toxicity.
- Type II groups proteins comprising two polypeptide chains A and B with distinct properties.
- the haptomer or B-chain (Binding), which contains a lectin domain, interacts with a sugar or a glycosylated compound on the surface of the cell and facilitates the entry of the A-chain into the cell.
- the effectomer, or chain A (Activity) carries the toxic activity.
- the best known of these toxins is ricin (from Ricinus communis), but other phytotoxins such as abrin (Abrus precatorius), modeccin (Adenai digitata), volkensin (Adenia volkensii) and viscum (from Viscum album), possess the same properties.
- Type 2 RIPs are much more efficient than Type 1 RIPs; indeed, although potent inhibitors of protein synthesis in acellular preparations, type 1 RIPs are much less toxic in mice (LD50 of 1 to 40 mg / kg) than type 2 RIPs (ricin LD50: 2 ⁇ g / kg).
- the suicide gene encodes a protein toxin of the RIP type 2 family or a protein derived, preferably for the chain A of a protein toxin of the RIP type 2 family such as ricin, abrin, modeccin, volkensin, viscumine and Shiga toxin, and particularly preferably for the ricin A chain.
- a protein toxin of the RIP type 2 family such as ricin, abrin, modeccin, volkensin, viscumine and Shiga toxin, and particularly preferably for the ricin A chain.
- the suicide gene corresponds to the sequence SEQ ID No: 2 or to a derived sequence.
- derivative sequence is meant a sequence having an identity of at least 80% with the sequence
- SEQ ID NO: 2 preferably at least 85%, especially at least 90%, and particularly preferably at least 95% identity.
- the 3'UTR region ranges from nucleotides 9378 to 9646 of the sequence having the accession number AF009606 for the genotype 1a; 9443 to 9678 of the sequence having accession number AB047639 for genotype 2a; 9444 to 9654 of the sequence having accession number AB030907 for genotype 2b; 9403-9628 of the sequence having accession number D84262 for genotype 6b; 9381-9615 of the sequence having accession number D84263 for genotype 6d; 9387-9621 of the sequence having the accession number D84264 for the 6k genotype.
- 3'UTR region of the genomic RNA (strand (+)) of the HCV is meant the 3'UTR region of the genomic RNA of a hepatitis C virus (HCV) of genotype 1, 2, 3 , 4, 5 or 6, or a sequence derived therefrom, preferably a genotype 1 hepatitis C virus.
- HCV hepatitis C virus
- derivative sequence is meant a sequence having an identity of at least 80% with the sequence of the 3'UTR region of the genomic RNA of a hepatitis C virus of genotype 1, 2, 3, 4, 5 or 6, preferably at least 85%, especially at least 90%, and particularly preferably at least 95% identity.
- sequence of the 3'UTR region of the HCV genomic RNA corresponds to the sequence SEQ ID No: 3 or to a sequence derived therefrom.
- the single-stranded RNA molecule according to the invention can be obtained by chemical synthesis methods or by molecular biological methods, in particular by transcription from DNA templates or plasmids isolated from recombinant microorganisms.
- this transcription step uses phage RNA polymerase such as T7, T3 or SP6 RNA polymerase.
- the single-stranded RNA molecule according to the invention corresponds to the sequence complementary to the sequence SEQ ID No. 4 or a derived sequence.
- derivative sequence is meant a sequence having an identity of at least 80% with the sequence
- SEQ ID NO: 4 preferably at least 85%, especially at least 90%, and particularly preferably at least 95% identity.
- a second subject of the invention corresponds to a DNA molecule, preferably double-stranded DNA, allowing transcription of the single-stranded RNA molecule described above.
- said DNA molecule comprises a nucleic acid sequence complementary to the nucleic acid sequence of the previously described single-stranded RNA molecule, which complementary nucleic acid sequence is operably linked to a sequence of nucleic acids. nucleic acid allowing its transcription in a eukaryotic or prokaryotic cell, preferably eukaryotic, and thus obtaining the single-stranded RNA molecule described above.
- Said DNA molecule thus makes it possible to obtain the single-stranded RNA molecule corresponding to a chimeric genomic RNA of negative polarity directly and without going through the successive steps of transcription of a chimeric genomic RNA of positive polarity and of replication of this genomic RNA. latest.
- transcriptional nucleic acid sequence any transcriptional regulatory sequence, such as a promoter or enhancer sequence, preferably a promoter sequence.
- Said promoter sequence may correspond, for example, to a cellular or viral promoter, and to a constitutive or inducible promoter.
- a constitutive or inducible promoter examples include, without limitation, the promoters of the following genes: hypoxanthine phosphoribosyltransferase (HPTR), adenosine deaminase, pyruvate kinase, ⁇ -actin, muscle creatine kinase and factor of human elongation.
- viral promoters having constitutive expression in mammalian cells include, but are not limited to, promoters of the following viruses: SV40, papilloma virus, adenovirus, human immunodeficiency virus (HIV) , Cytomegalovirus (CMV), Rous sarcoma virus (RSV), Hepatitis B virus (HBV).
- Other constitutive promoters are well known to those skilled in the art.
- Useful promoter sequences also include inducible promoters and allowing a transcription following the addition of an induetible agent.
- Other inducible promoters may simply be identified by those skilled in the art with regard to his general knowledge.
- the promoter sequence includes 5 'non-transcribed sequences involved in transcription initiation such as a TATA box.
- Another subject of the invention consists of a nucleic acid vector comprising a nucleic acid molecule as described above, in particular an RNA or DNA molecule.
- nucleic acid vector is meant any support for facilitating the transfer of said RNA or DNA molecules in the cells, preferably in the cells potentially infected with the hepatitis C virus.
- the vector according to the invention makes it possible to transport said nucleic acid molecules by limiting the degradation thereof with respect to their transport in the absence of a vector.
- the vector optionally comprises the promoter sequences described above.
- usable vectors mention may be made, without limitation, of plasmids, phagemids, viruses and other derived vectors of viral or bacterial origin.
- Preferred viral vectors include adenoviruses (modified), which are capable of infecting a very large number of species and cell types, lentiviruses (modified in particular by a modification of the envelope protein so as to obtain the tropism sought) or hepatitis A and B viruses (modified) which are capable of specifically infecting liver cells.
- Preferred non-viral vectors include those Plasmid vectors, which are extensively described in the prior art (see, for example, SlVNBROOK et al., "Molecular Cloning: A Laboratory Manual," Second Edition, CoId Spring Harbor Laboratory Press, 1989). Plasmids can be administered by multiple routes, including topical or parenteral. For example, the plasmids can be injected intramuscularly, intradermally, intrahepaticly or subcutaneously.
- the nucleic acid vector according to the invention may comprise active selection markers in eukaryotic and / or prokaryotic cells.
- Another object of the invention is a pharmaceutical composition
- a pharmaceutical composition comprising a nucleic acid molecule, RNA or DNA, or a vector as described above.
- said pharmaceutical composition comprises a pharmaceutically acceptable carrier.
- the compositions according to the invention may comprise emulsions, microemulsions, oil-in-water or water-in-oil emulsions, or other types of emulsions.
- the composition may also comprise one or more additives, such as diluents, excipients or stabilizers (see in particular ⁇ llmann's Encyclopedia of Industr ⁇ al Chemistry, 6 th Ed, 1989-1998, Marcel Dekker;.. ANSEL et al, Pharmaceutical Dosage Forms and Drug Delivery Systems, WILLIAMS & WILKINS, 1994).
- the composition may comprise water or a solubilization buffer, which buffers include, but are not limited to, phosphate buffered saline (PBS), phosphate buffered saline without Ca ++ / Mg ++ , saline (150 mM
- buffers include, but are not limited to, phosphate buffered saline (PBS), phosphate buffered saline without Ca ++ / Mg ++ , saline (150 mM
- Another object of the invention is the use of a nucleic acid molecule or a vector as described above for the preparation of a pharmaceutical composition for preventing or treating a replicating RNA virus by RNA dependent RNA polymerase in a patient.
- Another subject of the invention consists in the use of a nucleic acid molecule or a vector as described above for the preparation of a pharmaceutical composition intended to prevent or treat a virus infection.
- Hepatitis C (HCV) in a patient is another subject of the invention.
- patient is meant a mammal, preferably a man.
- composition according to the invention may be administered in a therapeutically effective amount by topical or parenteral route, in particular by intramuscular, intradermal, intrahepatic or subcutaneous injection, preferably by intrahepatic injection.
- composition according to the invention may be carried out by methods of gene transfer known to those skilled in the art.
- Common methods of gene transfer include calcium phosphate, DEAE-Dextran, electroporation, microinjection, viral methods and cationic liposomes (GRAHAM and VAN DER EB, Virol., Vol.52, p: 456, 1973; McCUTHAN and PAGANO, J. Natl Cancer Inst., Vol.41, p: 351, 1968; CHU et al., Nucl. Acids Res., Vol. 15, p: 1311; FRALEY et al., J. . Biol. Chem, vol.255, p: 10431, 1980; et al CAPECCHI f Ceil, vol 22, p... 479, 1980; FELGNER et al, Proc Natl Acad ScI USA, vol.84.... , p: 7413, 1988).
- an effective amount of nucleic acid molecules to be administered to a patient can be determined simply by the skilled person.
- an effective amount of nucleic acid molecules is between 0.001 mg and 10 g / kg of the patient to be treated, preferably between 0.01 mg and 1 g / kg, and particularly preferably between 0.1 and lOOmg / kg.
- a cellular system that constitutively synthesizes the HCV replication complex was developed by inserting non-structural HCV proteins (NS3-NS5B) into the cell genome of the Huh7 hepatoma cell line.
- NS3-NS5B non-structural HCV proteins
- a pcDNA3.1 / NS3-5B (2884R / G) vector encoding said nonstructural proteins was constructed as follows:
- the genes encoding nonstructural proteins spanning NS3 to NS5B were amplified from infectious isolate J4L6 of HCV, genotype 1a strain (YANAGI et al., Virology, vol.244 (1), p: 161 -72, 1998) using Herculase® polymerase (STRATAGENE) and NS3-Start primers (SEQ ID No. 5: ACACACTGGCCAATGGCGCCCATCACGGCCTACTCC) and NS5B-stop (SEQ ID No. 6: GTGTGTTCTAGATCATCGGTTGGGGAGCAGGTA).
- the NS3-5B fragment was then inserted between the EcoRV and XbaI sites of plasmid pcDNA3.1 (INVITROGEN), thereby producing the pcDNA3.1 / NS3-5B vector.
- a mutation of the GIy residue at Arg at position 2884 (PIETSCHMANN et al.) was then introduced by direct mutagenesis using the primers NS5B2884S (SEQ ID No 7: TCATTGAAGGGCTCCATGGTCTTAGCGCATTTACAC) and NS5B2884AS (SEQ ID No 8: TAAGACCATGGAGCCCTTCAATGATCTGAGGTAGGTC) and the Taq Phusion® DNA polymerase (OZYME).
- the PCR reaction was carried out on the vector pcDNA3.1 / NS3-5B, the PCR product obtained was then digested with the enzyme Dpn I (PROMEGA) and directly amplified in culture of E. coli DH5 ⁇ bacteria.
- the plasmid pcDNA3.1 / NS3-5B (2884R / G) containing the mutated sequence was selected by sequencing.
- Huh7 cells were therefore transfected with 2.5 ⁇ g of the plasmid vector ⁇ cDNA3.1 / NS3-5B (2884R / G) using lipofectin® plus reagent + (INVITROGEN) according to the instructions of the supplier.
- the cells were then cultured in modified Dulbecco's medium supplemented with 10% heat-inactivated fetal calf serum (FCS) and antibiotic G418 (1 mg / ml) at 37 ° C. under an atmosphere of 5% CO 2 .
- FCS heat-inactivated fetal calf serum
- antibiotic G418 (1 mg / ml)
- This 5UTR-H2AE-3UTR sequence consists of the 5'UTR region of HCV, a sequence coding for a polyprotein consisting of the sequences of the hygromycin resistance protein, the foot and mouth disease virus protein 2A ( FMDV) and the EGFP protein, followed by the 3 'NC region of HCV, was constructed.
- Step 1 The construction of the pGEM-T / 5UTR-EGFP-3UTR vector plasmid (FIG. 1A) was carried out by amplification of the 5'UTR and 3'UTR (or non-coding region) regions, respectively from the isolate conl and the strain. H77, and the EGFP (enhanced green fluorescent protein) gene.
- the 5 'NC sequence extended to the first 27 nucleotides encoding the capsid protein (protein C), was amplified using primers 5NC ⁇ Start (SEQ ID No 9: GCCAGCCCCCGATTGGGGGCG) and 5NC-Bam (SEQ ID No 10: ATAGGATCCGGTGTTACGTTTGGTTTTTC) and the isolate conl as template (EMBL X61596), the EGFP sequence was amplified by Taq Gold® polymerase (ROCHES) using EGFP-Bam primers (SEQ ID No 11
- the 3 'NC region was obtained by polymerase chain reaction (PCR) using the primers 3NC-Xba (SEQ ID No 13: ATATATTCTAGAACGGGGAGCTAAACACTCCAG) and 3NC-StOp (SEQ ID No 14: ACTTGATCTGCAGAGAGGCCAG) of the VHC strain H77 ( EMLB AF011753).
- the amplification product and the 5UTR-EGFP fragment were digested with the XbaI enzyme, ligated under the conditions described above and the ligation product obtained was amplified using the 5NC-Start and 3NC-stop primers.
- the resulting fragment was inserted into the pGEM-T vector plasmid (PROMEGA), producing the pGEM-T / 5UTR-EGFP-3UTR vector.
- the resulting pGEM-T / 5NC-EGFP-3NC vector sequence was confirmed by sequencing.
- the construction of the plasmid pGEM-T / 5UTR-H2AE-3UTR was carried out by the insertion of the sequence of hygromycin phosphotransferase (HygroR) and the sequence coding for the viral protein 2A. Foot and Mouth Disease Virus (FMDV) between the 5'UTR region and the EGFP sequence of the vector pGEM-T / 5UTR-EGFP-3UTR.
- HygroR hygromycin phosphotransferase
- FMDV Foot and Mouth Disease Virus
- the hygromycin sequence was obtained by PCR amplification of the psiSTRIKETM vector plasmid (PROMEGA) using Hygro-Bam primers (SEQ ID No. 15: ATATATGGATCCAAAAAGCCTGAACTCACCGCG) and Hygro2A-Bam (SEQ ID No. 16: ATATATGGATCCGGGCCCAGGGTTGGACTCGACGTCTCCCGCAAGCTTAAG AAGTTCCTTTGCCCTCGGACGAG ); which Hygro2A-Bam primer comprises the 42 nucleotides of the 2A protein sequence.
- the amplification product obtained was then inserted into the BamHI site of the plasmid pGEM-T / 5UTR-EGFP-3UTR, to obtain the vector pGEM-T / 5UTR-H2AE-3UTR. Finally, the resulting ⁇ GEM-T / 5UTR-H2AE-3UTR vector sequence was confirmed by sequencing.
- the T7 phage promoter required for transcription was introduced by PCR.
- (+) primers T7-5UTR SEQ ID No 17: TAATACGACTCACTATAGGGCCAGCCCCCTGATGGGGGCG
- 3UTR-STOP SEQ ID NO: 18: ACTTGATCTGCAGAGAGGCCAG
- T7-3UTR SEQ ID NO 19: TAATACGACTCACTATAGGACTTGATCTGCAGAGAGGCCAG
- 5UTR-Start SEQ ID No 20: GCCAGCCCCCGATTGGGGGCG
- RNA of negative polarity was obtained by transcription of 1 ⁇ g of PCR product using T7 polymerase (PROMEGA) following the instructions of the manufacturer. Finally, the RNAs were purified using an RNeasy® kit (QIAGEN) following the manufacturer's instructions.
- 24-well culture plates were seeded at 'of 10 5 cells Huh7 / NS3-5B per well and incubated 24 hours at 37 ° C.
- the cells obtained were then transfected with 1 ⁇ g of 5UTR-H2AE-3UTR positive polarity transcripts mixed with 3 ⁇ l of DMRIE-C (INVITROGEN) according to the supplier's recommendations.
- the cells thus transfected were cultured in the presence of different concentrations of hygromycin to select the cells replicating the transfected transcript.
- Huh7 / NS3-5B cells transfected or not with 5UTR-H2AE-3UTR transcripts and in the presence of different concentrations of hygromycin were trypsinized and resuspended at a concentration of 0.5 ⁇ 10 6 to 1.10 6 cells. / ml in 2mM EDTA phosphate buffer.
- the resulting cell suspensions were then analyzed by flow cytometry at 488 nm to detect expression of EGFP and using a FACS Calibur® (BECKTON).
- Figure 2A shows the percentage of Huh7 fluorescent transfected cells (striped), Huh7 / NS3-5B (black) and Huh7 / Rep5.1 (gray, cf.3) at 24, 48 and 72 hours post transfection.
- FIG. 2B shows the fluorescence index corresponding to the fluorescence ratio between the Huh7 and Huh7 / NS3-5B transfected cells (black), and between the Huh7 and Huh7 / Rep5.1 transfected cells (gray, cf. 3).
- cells of the Huh7 / NS3-5B cell line which constitutively express the NS3-NS5B polyprotein, allow the production of an efficient replication complex for replication of the mini-genome.
- Huh7 / Rep5.1 cells Huh7 / Rep5.1 cells, KRIEGER et al., J. Virol., Vol.75, p .4614-4624.
- Huh7 / Rep5.1 and Huh7 cells were transfected with 1 ⁇ g of 5UTR-H2AE-3UTR transcripts of positive polarity according to the protocol described in 2-2.
- the expression of the EGFP protein was analyzed after 24, 48 and 72 hours by flow cytometry (FIG. 2A).
- expression of the EGFP protein is represented as the percentage of expression of EGFP by Huh7 / rep5.1 cells relative to the expression level of Huh7 cells. .
- Huh7 / Rep5.1 cells are cultured under selection pressure as opposed to Huh7 / NS3-5B cells, EGFP expression difference between these two cell lines likely reflects a lower cellular permissivity of Huh7 / NS3-5B cells in the absence of selection pressure.
- genomic RNAs of negative polarity derived from HCV were able to replicate in cells harboring a replicon.
- a chimeric genomic RNA was constructed as previously in which the transgene corresponded, not to EGFP, but to the gene coding for the ricin A chain flanked by the 5'UTR and 3'UTR regions of the HCV (5UTR-Ric-3UTR).
- the ricin A chain gene has been selected as a suicide gene on the basis of its high toxicity to eukaryotic ribosomes of HCV-infected target cells (EIKLID et al., Exp. vol.126 (2), p: 321-6, 1980; OLSNES and KOZLOV, Toxicon, vol.39 (11), p: 1723-1728, 2001), and for its non-diffusivity in the absence of the B-chain thus preserving healthy surrounding cells that do not express the HCV replication complex.
- the gene coding for the ricin A chain was obtained by PCR amplification using the Ric_Start primers (SEQ No 21:
- the gene coding for the ricin A chain was introduced into the pGEM-T / 5UTR-EGFP-3UTR plasmid by exchanging the EGFP gene with that of the ricin A chain at the BamHI and XbaI sites, producing plasmid pGEM-T / 5UTR-Ric-3UTR (FIG. 1C).
- the T7 phage promoter required for transcription was introduced by PCR. In order to transcribe the (+) strand the primers T7-5UTR (SEQ ID No. 17) and 3UTR-ST0P (SEQ ID No. 18) were used. In order to transcribe the (-) strand the primers T7-3UTR (SEQ ID No. 19) and 5UTR-Start (SEQ ID No. 20) were used.
- RNA of negative polarity was obtained by transcription of 1 ⁇ g of PCR product using T7 polymerase (AMBION) following the instructions of the manufacturer.
- the minimal genomic RNA of negative polarity obtained is constituted, starting from the 5 'end towards the 3' end, by the complementary sequences of: the 3 'non-coding region of HCV (3'UTR), the ricin A sequence, the first 27 nucleotides of the coding sequence for the capsid protein, and finally the 5 'non-coding region of HCV.
- FIG. 3 shows the sequence of genomic RNA of positive polarity with the ricin A chain sequence (underlined), framed by the cloning sites (bold and italic) and the 5'UTR (high) and 3 regions. '-UTR (low).
- Huh7 / Rep5.1 and Huh7 / NS3-5B cells were transfected with the minimal genomic RNA of negative polarity obtained in 4-1 according to the protocol described in 2-2.
- Huh7 cells were transfected with the minimal genomic RNA of negative polarity obtained in 4-1 according to the same protocol.
- Figure 4 shows the cytotoxicity 48 hours after transfection of Huh7, Huh7 / Rep5.1 or Huh7 / NS3-5B cells with minimal genomic RNA of negative (black) or positive (gray) polarity.
- FIG. 5 corresponds to the normalization of the percentage of cytoxicity of the negative-polarity minimal genomic RNA by taking as a transfection reference (100%) the percentage of cytoxicity of the positive-polarity minimal genomic RNA.
- the results show that the developed suicide vector, corresponding to a negative-polarity HCV-derived RNA molecule, is effective in targeting and destroying cells expressing genotype Ib HCV replication complexes.
- the inventors have also been able to show that the same suicide vector developed is effective for targeting and destroying (at nearly 90%) Huh7 cells infected with a genotype 2a HCV virus (JFH-I, ZHONG et al., Proc Natl Acad Sci USA, vol.102 (26), p: 9294-9, 2005).
- a chimeric genomic RNA was constructed as described above, in which the transgene corresponded to the gene coding for either interferon alpha (IFN- ⁇ ) either for the Interferon Regulatory Factor (IRF-I) by the 5'UTR and 3'UTR regions of the HCV (5UTR-Ric-3UTR).
- IFN- ⁇ interferon alpha
- IRF-I Interferon Regulatory Factor
- the gene coding for IFN- ⁇ was obtained by PCR amplification using the IFN-Bam primers (SEQ ID No. 23: ATATATGGATCCGCCCTGTCCTTTTCTTTACTGATGG) and IFN-Xba (SEQ ID NO: 24: ATATATTCTAGATCAATCCTTCCTCCTTAATATTTTTTGC).
- IRF-I The gene coding for IRF-I was obtained by PCR amplification using IRF1-Bam primers (SEQ ID No. 25: ATATATGGATCCCCCATCACTCGGATGCGCATG) and IRF1-Xba (SEQ ID No. 26: ATATATTCTAGACTACGGTGCACAGGGAATGGC).
- the genes coding for IFN- ⁇ and IRF-I were introduced into the plasmid pGEM-T / 5UTR-EGFP-3UTR at the BamHI and XbaI sites, producing the plasmid pGEM-T / 5UTR-IFN ⁇ -3UTR and pGEM. -T / 5UTR-IRFl-3UTR.
- the T7 phage promoter required for transcription was introduced by PCR. In order to transcribe the (+) strand the primers T7-5UTR (SEQ ID No. 17) and 3UTR-ST0P (SEQ ID No. 18) were used. In order to transcribe the (-) strand the primers T7-3UTR (SEQ ID No. 19) and 5UTR-Start (SEQ ID No. 20) were used.
- RNA of negative polarity was obtained by transcription of 1 ⁇ g of PCR product using T7 polymerase (AMBION) following the manufacturer's instructions.
- the minimum genomic RNA of negative polarity obtained is constituted, starting from the 5 'end towards the end
- IRF-I the first 27 nucleotides of the coding sequence for the capsid protein, and finally the 5 'non-coding region of HCV.
- RNA of positive polarity was also produced following the same protocol and in vitro transcription with T3 polymerase (AMBION) following the manufacturer's instructions.
- AMBION T3 polymerase
- Huh7 / Rep5.1 cells were transfected with the minimal genomic RNA of negative polarity obtained in 5-1 according to the protocol described in 2-2.
- Huh7 / Rep5.1 cells were transfected with the 5UTR-EGFP-3UTR minimal genomic RNA, of positive polarity obtained in 2-1, step 1 according to the same protocol.
- FIG. 6 shows the effects of IFN minigenomes
- Huh7 / Rep5.1 cells were transfected with the minimal positive (+) or negative (-) polynomial RNAs expressing IFN ⁇ or IRF-I.
- FIG. 6A illustrates the number of RNA copies of the replicon measured by real-time quantitative RT-PCR, reported per ⁇ g of total RNA after 48 hours of culture.
- the minimal genomic RNA 5UTR-EGFP-3UTR was transfected as a control.
- One hundred IU of IFN- ⁇ was added to the cell culture (IFN 100 IU) as a positive control.
- Figure 6B illustrates the percentage inhibition of Rep 5.1 replicon replication calculated by taking the RNA 5UTR-EGFP-3UTR minimal genomic as replication control.
- the results show that vectors stimulating the antiviral cellular response, corresponding to an HCV-derived and negative polarity-derived RNA molecule, are effective in targeting cells expressing the HCV replication complex and reducing the number of RNAs. genomic replicon.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0604806A FR2901807B1 (fr) | 2006-05-30 | 2006-05-30 | Nouveau traitement d'une infection par le vhc |
PCT/FR2007/000899 WO2007138193A1 (fr) | 2006-05-30 | 2007-05-30 | Traitement d'une infection par un virus a arn a une arn polymerase arn dependante |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2021482A1 true EP2021482A1 (fr) | 2009-02-11 |
Family
ID=37726550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07765973A Withdrawn EP2021482A1 (fr) | 2006-05-30 | 2007-05-30 | Traitement d'une infection par un virus à arn à une arn polymérase arn dépendante |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110015255A1 (fr) |
EP (1) | EP2021482A1 (fr) |
JP (1) | JP5301433B2 (fr) |
CA (1) | CA2653910A1 (fr) |
FR (1) | FR2901807B1 (fr) |
WO (1) | WO2007138193A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9775894B2 (en) * | 2013-07-09 | 2017-10-03 | University Of Washington Through Its Center For Commercialization | Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19915178A1 (de) * | 1999-04-03 | 2000-10-05 | Univ Mainz Johannes Gutenberg | Hepatitis C Virus Zellkultursystem |
US20010055756A1 (en) * | 2000-04-21 | 2001-12-27 | Charles Pellerin | Internal de novo initiation sites of the HCV NS5B polymerase and use thereof |
AU2001282417A1 (en) * | 2000-07-24 | 2002-02-05 | Institute Of Molecular & Cell Biology | Nucleic acids and methods for detecting viral infection, uncovering anti-viral drug candidates and determining drug resistance of viral isolates |
CA2437072A1 (fr) * | 2001-01-31 | 2002-08-08 | Bristol-Myers Squibb Pharma Company | Systeme in vitro pour la replication de virus a arn polymerase arn dependante |
EP1735470B1 (fr) * | 2004-03-24 | 2010-04-21 | Achillion Pharmaceuticals, Inc. | Test quantitatif dans la detection d'un arn recemment synthetise dans un systeme exempt de cellules et identification des inhibiteurs de synthese de l'arn |
-
2006
- 2006-05-30 FR FR0604806A patent/FR2901807B1/fr not_active Expired - Fee Related
-
2007
- 2007-05-30 EP EP07765973A patent/EP2021482A1/fr not_active Withdrawn
- 2007-05-30 JP JP2009512639A patent/JP5301433B2/ja not_active Expired - Fee Related
- 2007-05-30 WO PCT/FR2007/000899 patent/WO2007138193A1/fr active Application Filing
- 2007-05-30 US US12/302,678 patent/US20110015255A1/en not_active Abandoned
- 2007-05-30 CA CA002653910A patent/CA2653910A1/fr not_active Abandoned
Non-Patent Citations (2)
Title |
---|
"Taxonomie des virus infectant les vertébrés", Retrieved from the Internet <URL:www.microbes-edu.org/etudiant/taxonomie.html> [retrieved on 20150212] * |
See also references of WO2007138193A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007138193A1 (fr) | 2007-12-06 |
WO2007138193A8 (fr) | 2009-07-16 |
JP5301433B2 (ja) | 2013-09-25 |
JP2009538610A (ja) | 2009-11-12 |
US20110015255A1 (en) | 2011-01-20 |
FR2901807A1 (fr) | 2007-12-07 |
FR2901807B1 (fr) | 2013-08-23 |
CA2653910A1 (fr) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jiang et al. | Picornavirus morphogenesis | |
You et al. | 3′ RNA elements in hepatitis C virus replication: kissing partners and long poly (U) | |
US7767210B2 (en) | RNA virus vaccines and methods | |
ES2376354T3 (es) | Nueva part�?cula recombinante similar al virus de la hepatitis c humano y procedimiento para producir la misma. | |
WO2004104198A1 (fr) | Construit d'acide nucleique contenant le virus de l'hepatite c (v h c) de l'acide nucleique d'origine du genome de genotype 2a et des cellules possedant ce construit d'acide nucleique transfere dans celles-ci | |
JP2010029212A (ja) | C型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 | |
BR112015026531B1 (pt) | Cromossomos artificiais bacterianos, seus usos, e método para preparar uma vacina contra vírus de rna | |
Hunziker et al. | Deletions within the 5′ UTR of coxsackievirus B3: consequences for virus translation and replication | |
JP2013198486A (ja) | Hcv遺伝子 | |
EP2021482A1 (fr) | Traitement d'une infection par un virus à arn à une arn polymérase arn dépendante | |
JP5693957B2 (ja) | Hcv/gbv−bキメラウイルス | |
ES2341800T3 (es) | Sistema de produccion elevada de particulas infecciosas del virus de la hepatitis c. | |
CA2539457C (fr) | Acide nucleique et gene provenant d'une nouvelle souche vhc et cellule a replication autonome comprenant ce gene | |
Nawtaisong et al. | Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7. 5 cells | |
JP2008541754A (ja) | Hcv特異的な低分子干渉rnaおよびそれを含むc型肝炎の治療剤 | |
Dumas et al. | The hepatitis C virus minigenome: a new cellular model for studying viral replication | |
CN113862231B (zh) | 一种3a型丙肝病毒亚基因组复制子及应用 | |
Afridi et al. | CLONING, PHYLOGENETIC AND EXPRESSION ANALYSIS OF NS2 GENE FROM HCV INFECTED PATIENTS IN PESHAWAR | |
Walther | Functional characterization of nonstructural protein 2 of closely related Flaviviridae members | |
US20110124086A1 (en) | Hepatitis C Virus Culture System | |
JP2005510455A (ja) | 抗ウイルス剤 | |
WO2024063694A1 (fr) | Procédé d'atténuation de flavivirus | |
KR20220124171A (ko) | 결손간섭입자 | |
KR101384860B1 (ko) | 표적 물질 특이적으로 siRNA를 방출하는 RNA 간섭용 조성물 및 이를 이용한 HCV 관련 질환 치료용 조성물 | |
US7790448B2 (en) | Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081128 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS Owner name: UNIVERSITE VICTOR SEGALEN BORDEAUX 2 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DUMAS, ESTELLE Inventor name: LITVAK, SIMON Inventor name: ASTIER-GIN, THERESE Inventor name: VENTURA, MICHEL |
|
17Q | First examination report despatched |
Effective date: 20090326 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS Owner name: UNIVERSITE BORDEAUX SEGALEN |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150630 |